Prognostic factors in patients with advanced pancreatic adenocarcinoma treated with intra-arterial chemotherapy

Pancreas

Volumn 36, Issue 1, 2008, Pages 56-60

  Mambrini, Andrea ^a   Bassi, Claudio ^b   Pacetti, Paola ^a   Torri, Tito ^a   Iacono, Calogero ^b   Ballardini, Michela ^c   Orlandi, Massimo ^a   Guadagni, Stefano ^d   Fiorentini, Giammaria ^e   Cantore, Maurizio ^a,f  

^a Hospital of Massa Carrara   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c MORGAGNI PIERANTONI HOSPITAL   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

^e SAN GIUSEPPE HOSPITAL   (Italy)

^f Carrara City Hospital   (Italy)

Author keywords

Intra arterial chemotherapy; Pancreatic cancer; Prognostic factors

Indexed keywords

CARBOPLATIN; EPIRUBICIN; FAMOTIDINE; FLUOROURACIL; FOLINIC ACID; GRANISETRON;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELIAC ARTERY; COMBINATION CHEMOTHERAPY; DRUG FATALITY; FEMALE; HEART INFARCTION; HEMATEMESIS; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA AND VOMITING; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; LEUCOVORIN; MALE; MIDDLE AGED; PAIN; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 38149007194     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/mpa.0b013e31812e9672     Document Type: Article

References (30)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2005;55:10-30.
2. Hafin SA, Schmiegel WH. Recent discoveries in cancer genetics of exocrine pancreatic neoplasia. Digestion. 1998;59:493-501.
3. Wagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91:586-594.
4. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.
5. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994;12:29-34.
6. O'Connell MJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. Cancer. 1989;63:1026-1030.
7. Buroker TR, O'Connell MJ, Wieand HJ, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol. 1994;12:14-20.
8. Anderson JS, Burris HA, Casper E, et al. Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol. 1994;13:461. [abstract 1600].
9. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403-2413.
10. Tas F, Aykan F, Alici S, et al. Prognostic factors in pancreatic carcinoma. Am J Clin Oncol. 2001;24(6):547-550.
11. Ikeda M, Okada S, Tokuuye K, et al. Prognostic factors in patients with locally pancreatic carcinoma receiving chemoradiotherapy. Cancer. 2001;91:490-495.
12. Watanabe I, Sasaki S, Konishi M, et al. Onset symptoms and tumor locations as prognostic factors of pancreatic cancer. Pancreas. 2004;28:160-165.
13. Okusaka T, Okada S, Ueno H, et al. Abdominal pain in patients with resectable pancreatic cancer with reference to clinicopathologic findings. Pancreas. 2001;22:279-284.
14. Fujimoto K, Hosotani R, Wada M, et al. Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer. 1998;34:1439-1447.
15. Nakata B, Wang YQ, Yashiro M, et al. Prognostic value of microsatellite instability in resectable pancreatic cancer. Clin Cancer Res. 2002;8:2536-2540.
16. Biankin AV, Kench JG, Morey AL, et al. Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res. 2001;6:8830-8837.
17. Cantore M, Pederzoli P, Cornalba G, et al. Intra-arterial chemotherapy for unresectable pancreatic cancer. Ann Oncol. 2000;11:569-573.
18. Cantore M, Fiorentini G, Luppi G, et al. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother. 2004;16:589-594.
19. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
20. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187-220.
21. Cunningham D, Chau I, Stocken D, et al. Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur J Cancer. 2005;3:12. [abstract 11].
22. Hermann R, Bodoki G, Ruhstaller T, et al. Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). J Clin Oncol. 2005;23. [abstract 4010].
23. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2006;15:3509-3516.
24. Poplin E, Levy DE, Berlin J, et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer. J Clin Oncol. 2006;24. [abstract 4004].
25. Banu E, Oudard S, Banu A, et al. Cumulative meta-analysis of randomized trials comparing gemcitabine-based chemotherapy versus gemcitabine alone in patients with advanced or metastatic pancreatic cancer. J Clin Oncol. 2005;23. [abstract 4101].
26. Reni M, Cordio S, Milandri C, et al. Gemcitabine versus cisplatin, epirubicin, 5-fluorouracil, gemcitabine in advanced pancreatic cancer: a phase III trial. Lancet Oncol. 2005;6:369-376.
27. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trial Group (NCIC-CTG). J Clin Oncol. 2005;3: [abstract 77].
28. Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: a preliminary analysis of cancer and leukemia group B. In: Proceedings of the 2007 Gastrointestinal Cancer Symposium, 19-21 January, 2007. Orlando, FL. [Abstract 108].
29. Appelqvist P, Viren M, Minkkinen J, et al. Operative finding, treatment, and prognosis of carcinoma of the pancreas: analysis of 267 cases. J Surg Oncol. 1983;23:143-150.
30. Ridder GJ, Klempnauer J. Back pain in patients with ductal pancreatic cancer. Its impact on resectability and prognosis after resection. Scand J Gastroenterol. 1995;30:1216-1220.